DSM Resins & Functional Materials

DSM introduces breakthrough low-toxicity crosslinkers with high functional performance

Waalwijk (NL), 2 March 2020 - Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, today announced the launch of a new, highly innovative crosslinker portfolio, NeoAdd™ PAX, with an unparalleled combination of low-toxicity and high-performance profile. The new, patent pending DSM polymeric aziridine crosslinker products will drive safety across a wide range of industries and exemplifies DSM’s commitment to using science to develop sustainable solutions that outperform conventional market alternatives.

Around the world, end consumers and regulatory bodies are increasingly concerned by the potential toxicity of crosslinking solutions. Currently available carbodiimide crosslinkers typically offer lower toxicity but compromise functional performance, while traditional aziridine crosslinkers will deliver higher levels of performance but potentially impact the health of people and planet. In line with its ambitious commitment to phase out all Chemicals of High Concern from its final products by 2025, DSM has developed a novel polymeric aziridine technology to deliver high levels of processability and functional performance as well as very low toxicity.

In particular, thanks to its unique chemical design and high molecular weight, the product family NeoAdd™ PAX delivers outstanding chemical and water resistance plus excellent adhesion to a wide range of substrates and requires no stoving or heating after application. It offers key functional performance advantages compared to most carbodiimide-based waterborne coating systems as higher chemical resistance can be achieved at lower dosing levels. What’s more, NeoAdd™ PAX is fully REACH compliant and, because of its low toxicity profile, dramatically decreases the labeling requirements compared with conventional aziridine crosslinkers.

As such, NeoAdd™ PAX will open new possibilities to a diverse set of markets, including industrial, architectural, packaging, ink, adhesives and leather coatings. The first two products are NeoAdd™ PAX-523, specially designed for use in waterborne industrial and architectural coating systems where superior performance is required and NeoAdd™ PAX-521 for usage in waterborne primers, inks and coatings for packaging applications.

Jon Cronin, Global Innovation Growth Leader DSM Coating Resins: “The new NeoAdd™ PAX crosslinker family aligns perfectly with our purpose-led, performance-driven strategy; this is a sustainable solution that works for both people and planet. Our new crosslinker is a breakthrough innovation in that it competes with traditional aziridines on functional performance but offers significant safety and sustainability benefits to many different industries and markets. I’m very proud that, more than ever, our bright science is being used to enable brighter living!”

Reader enquiries

DSM Resins & Functional Materials
Sluisweg 12
PO Box 123
5140 AC Waalwijk
Netherlands
+31 (0)416 689911
www.dsm.com

Notes for editors

DSM – Bright Science. Brighter Living.™

Royal DSM is a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM’s purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world’s biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

Related images

DSM introduces breakthrough low-toxicity crosslinkers with high functional performance.

 

Editorial enquiries

Marjolein Bijsterveld
Marketing Communications Manager
DSM

+31 (0)6 2571 3729
marjolein.bijsterveld@​dsm.com

Inka Finne
EMG

+31 164 317 019
ifinne@​emg-marcom.com

 

Also available in

 

Share